Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Monthly Archives: June 2010

10 06, 2010

Now That ASCO Is Over, Companies Start Releasing News About Failed Multiple Myeloma Studies

Tags: , , |0 Comments

I don't think it is a coincidence that news about this failed study was released post-ASCO.  Who wants to discuss failure in front of 100,000 clinicians, cancer docs and researchers!  Expect more announcements like this in the weeks and months to come:The Associated Press June 9, 2010Human Genome Sciences says cancer drug fails studyROCKVILLE, Md.

8 06, 2010

The Truth About The New Multiple Myeloma Novel Therapy Drug, Carfilzomib

Tags: , , , , |3 Comments

Is Onyx Pharmaceuticals' new, next generation proteasome inhibitor a new miracle drug—or just another “bit player” on the multiple myeloma scene? It depends who you ask.The company is pushing comparisons with the only currently available FDA proteasome inhibitor, Velcade. Company officials point to ongoing research study results which show less risk of developing peripheral neuropathy

5 06, 2010

Follow-Up Analysis Of Onyx Pharmaceuticals’ Carfilzomib 004 Study Against Refractory Multiple Myeloma

Tags: , , , |1 Comment

Onyx Pharmaceuticals' Carfilzomib Highlights First Day Of ASCO Meetings In ChicagoFlaunting an impressive 55% success rate in previously treated multiple myeloma patients, Onyx Pharmaceuticals revealed the results of their ongoing Phase 2 clinical carfilzomib study, 004 at the American Society of Clinical Oncology (ASCO) meetings here in Chicago.Carfilzomib is a selective, next-generation proteasome inhibitor, similar

4 06, 2010

Long Anticipated Phase 2 Carfilzomib Study 004 Doesn’t Disappoint!

Tags: , , |2 Comments

Here is the first of two major announcements by Onyx Pharmaceuticals concerning their new multiple myeloma drug carfilzomib:Onyx Pharmaceuticals’ Carfilzomib Continues to Demonstrate Encouraging Results in Ongoing Phase 2 Multiple Myeloma StudyFifty-five Percent Single-Agent Response Rate in Relapsed/Refractory SettingEmeryville, CA – June 5, 2010 – Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced interim results from

4 06, 2010

Navigating ASCO

Tags: |0 Comments

Well, I’ve begun to learn my way around McCormick place. There is a large, central building (East Hall) which houses registration and a number of presentation rooms. Crossing over by sky-walk heading west, you enter a huge, glass covered atrium and exhibit hall. This is where all of the drug and medical equipment companies have

4 06, 2010

Checking-In From ASCO

Tags: , |0 Comments

Oh my God!  I I don't know how I ever would have managed driving into the city and finding the press room here at McCormick Place if I hadn't grown up in the Chicago area... Traffic is crazy, parking unclear and the facility is massive!   I'm hiding here in the press room and preparing for

3 06, 2010

Multiple Myeloma Research Consortium (MMRC) Announces Data Presentations At ASCO

Tags: , , , |0 Comments

More pre-ASCO news:Multiple Myeloma Research Consortium (MMRC) Announces Data Presentations at 46th Annual American Society of Clinical Oncology (ASCO) Annual MeetingThe Multiple Myeloma Research Consortium (MMRC) today announced the presentation of studies conducted through its clinical sites in collaboration with industry partners, Onyx Pharmaceuticals and Bristol-Myers Squibb, in evaluating promising new therapeutic agents for multiple